(CIDRAP News) – A new analysis of H7N9 genetic sequences from the first Chinese patients infected with the virus and from poultry markets found more signals that the virus can attach and replicate efficiently in the airways of humans and other mammals, raising concerns about the virus's pandemic potential.
Swine reassortant suggests 2009 H1N1 virus could cause more troubleScientists have found a hybrid influenza virus in swine that combines elements of the pandemic 2009 H1N1 virus and a Eurasian swine flu virus, suggesting that continued circulation of the pandemic virus in pigs could lead to novel viruses with the ability to infect humans, according to a report published yesterday in the Journal of Virology. The detection of the pandemic virus in pigs prompted a flu
(CIDRAP News) – A five-country study from Europe indicates that the use of adjuvanted vaccines against the pandemic H1N1 influenza virus probably did not increase the risk of Guillain-Barre syndrome (GBS), but the investigators could not firmly rule out a slightly greater chance of suffering the paralytic condition.
(CIDRAP News) Scientists have found evidence that North American avian influenza viruses of the H7 subtype are becoming more like human flu viruses in their ability to attach to host cells, which suggests they may be improving their capacity to infect humans.
(CIDRAP News) A recently published survey of Europeans and Asians showed that, when faced with an influenza pandemic, most would avoid mass transit and limit shopping to essentials, and many would avoid other public places, including restaurants, theaters, and the workplace.
(CIDRAP News) – The European Union (EU) has approved Novartis's seasonal influenza vaccine, Optaflu, putting the Swiss company in a position to become the first to market a flu vaccine grown in cell culture rather than eggs.
(CIDRAP News) In an effort to modernize vaccine production while preparing for an influenza pandemic, the US government today awarded five contracts totaling more than $1 billion to develop cell-based technologies for making flu vaccines.